Volume | 654,883 |
|
|||||
News | - | ||||||
Day High | 35.015 | Low High |
|||||
Day Low | 34.07 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Agios Pharmaceuticals Inc | AGIO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
35.00 | 34.07 | 35.015 | 34.34 | 35.00 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
7,755 | 654,883 | $ 34.63 | $ 22,676,600 | - | 19.795 - 35.48 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:05:25 | 1 | $ 33.66 | USD |
Agios Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.93B | 56.19M | - | 26.82M | -352.09M | -6.27 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Agios Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AGIO Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 32.94 | 35.33 | 32.45 | 34.12 | 493,892 | 1.40 | 4.25% |
1 Month | 29.27 | 35.48 | 28.71 | 32.70 | 694,237 | 5.07 | 17.32% |
3 Months | 29.87 | 35.48 | 27.14 | 31.42 | 725,683 | 4.47 | 14.96% |
6 Months | 22.47 | 35.48 | 20.96 | 27.34 | 714,954 | 11.87 | 52.83% |
1 Year | 25.70 | 35.48 | 19.795 | 26.33 | 590,905 | 8.64 | 33.62% |
3 Years | 54.96 | 62.155 | 16.75 | 30.90 | 598,576 | -20.62 | -37.52% |
5 Years | 49.15 | 62.155 | 16.75 | 36.61 | 640,891 | -14.81 | -30.13% |
Agios Pharmaceuticals Description
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval. |